Institut Pasteur

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur and Centre National De La Recherche Scientifique

Assistance Publique-hopitaux De Paris

Université Pierre Et Marie Curie

Philippe Kourilsky

Jean-Luc Guesdon

Stratis Avrameas

Jean-Pierre Abastado

Estelle Mottez

Claude Roth

Lluis M Mir

Christophe Pannetier

Brigitte Cami, Born Contamine

Madeleine Cochet

David Klatzmann

Jean-Loup Salzmann

Yu-Chun Lone

Yousuke Takahama

Armanda Casrouge

Sylvie Darche

Brigitte Cami Contamine

Irina Apostolov

Brigitte Cami Nee Contamine

Gabriel Gachelin

David Ojcius

The invention concerns a pharmaceutical composition comprising at least a PIM-activated NKT cell and the use of at least one PIM and/or a PIM-activated NKT cell for treating a disease for which a granulomatous type of immune response is desired.

Method for activating NKT cells using PIMs

An altered MHC class I determinant comprises .alpha..sub.1, .alpha..sub.2, .alpha..sub.3, .beta..sub.2 -microglobulin (.beta..sub.2 m) polypeptide domains encoded by a mammalian MHC class I locus in which the .alpha..sub.3 domain is covalently linked to the .beta..sub.2 M domain. An altered MHC class II determinant comprises .alpha..sub.1, .alpha..sub.2, .beta..sub.1, and .beta..sub.2 polypeptide domains encoded by a mammalian MHC class II locus, in which the domains are covalently linked to form a polypeptide comprising the .beta..sub.2 -.alpha..sub.2 -.alpha..sub.1 -.beta..sub.1 domains in sequence. The altered MHC class I and class II determinants can be associated with an antigen to elicit an immune response. The invention can be used in the immunization or treatment of diseases such as AIDS, multiple sclerosis, lupus erythematosus, toxic shock or snake bite.

Altered major histocompatibility complex (MHC) determinant and methods

Composition for use in the treatment of tumors and the immunization of humans or animals comprising a synergistic association of cells, viruses, or bacteria expressing, transitorily, in organisms at least one gene for producing in vivo one or more immunomodulators, and viruses, or cells producing viruses, said viruses preferably infecting dividing cells of the treated organisms and carrying within their genome at least one gene whose expression in the dividing cells will cause their destruction.

Composition comprising interleukin-2 and thymidine kinase for the

Composition designed to treat human or animal organisms comprising cells expressing genes enabling them to secrete in vivo one or more biologically-active substances, said cells exhibiting genetic characteristics preventing them from growing durably in the treated organism, and making them susceptible to elimination artificially or naturally from the organism. These compositions can be used in particular in the treatment of tumors or cancers, in which case the substances used are interleukins. The cells contained in these compositions are at least partially allogenic or xenogenic.

Cellular composition for the treatment of human or animal organisms

An altered MHC class II determinant comprises .alpha..sub.1, .alpha..sub.2, .beta..sub.1, .beta..sub.2, domains of a mammalian MHC class II locus in which the domains are covalently linked to form a construct comprising the .beta..sub.2 -.alpha..sub.2 -.alpha..sub.1 .beta..sub.1 domains in sequence. The altered class II determinants can be associated with an antigen to elicit an immune response. In addition, the altered determinants may be used to prepare antibodies. The antibodies so produced have various diagnostic and therapeutic uses.

Altered major histocompatibility complex (MHC) determinant and method of

Method for detecting the possible presence of a DNA fragment, notably of a gene, in the midst of a complex sample of nucleic acids. It comprises the hybridization of the sought fragment with a RNA probe, this being, prior or subsequent to the hybridization reaction, modified by an enzyme. Application to seeking of particular genes or DNA fragments in the midst of a biological sample.

Method of detecting and characterizing a nucleic acid or reactant for

Method of detecting and characterizing a nucleic acid or a sequence of

The present invention relates to a process for determining the quantity of a DNA fragment of interest in a sample wherein:

Process for determining the quantity of a DNA fragment of interest by a

In a method for describing repertoires of antibodies (Ab) and T cell recers (TcR) of the immune system of an individual, reverse transcription is carried out on the mRNA contained in a biological sample, separate amplifications are then carried out on the transcription product (or directly on the DNA extracted from the sample) by a PCR type method for each primer pair V, C, where V corresponds to a variable segment of the repertoire of interest and C hybridizes on the constant segment of the repertoire of interest. For each J segment of the labelled repertoire, an elongation step is carried out on each of the amplification products using a specific oligonucleotide of this segment J as primer and the amplification product as matrix. For each elongation product corresponding to a triplet (V, C)J thus obtained, the size of the different elongation products is revealed. The description of the repertoires corresponds to a VCJ triplet and to the element size for each element of the repertoire.

Method for describing the repertoires of antibodies (Ab) and of T-cell

Detection methods and compositions of matter comprising an enzyme coupled to a nucleic acid are disclosed. A complex of the enzyme-nucleic acid hybridized to a nucleic acid to be detected is also disclosed. The nucleic acid is detected by measuring the activity of the enzyme.

Growing community of inventors

Paris, France

Philippe Kourilsky